Suppressed COVID Vaccine Study Published Shows 50-55% Protection Against Hospitalization
A CDC-blocked vaccine effectiveness study finds 2025-2026 COVID shots cut hospitalization risk by 55% and ER visits by 50% in adults.
Summary
A COVID vaccine effectiveness study blocked by CDC acting director Jay Bhattacharya has been published in JAMA Network Open. The case-control study found the 2025-2026 COVID vaccine reduced emergency department visits by 50% and hospitalizations by 55% among adults. Among adults 65 and older, protection was slightly lower at 48% and 53% respectively. The study used a test-negative design, a method used by the CDC for decades to monitor flu vaccine effectiveness. Bhattacharya had questioned this methodology, but public health researchers defend it as a validated, efficient real-world evaluation tool. The findings reinforce that updated COVID vaccines continue to provide meaningful protection against severe illness, even amid evolving variants.
Detailed Summary
A peer-reviewed COVID-19 vaccine effectiveness study that was suppressed by CDC acting director Jay Bhattacharya earlier in 2026 has now been published in JAMA Network Open, reigniting debate about scientific censorship and public health transparency.
The core findings are clinically significant. The case-control study examined the first four months of the 2025-2026 COVID season and found that updated COVID vaccines provided 50% protection against emergency department and urgent care visits and 55% protection against hospitalizations among adults broadly. For adults 65 and older, a high-risk group, protection was 48% and 53% respectively — still meaningful reductions in severe outcomes for the most vulnerable population.
The study was originally slated for publication in the CDC's Morbidity and Mortality Weekly Report in March 2026 but was blocked after Bhattacharya objected to its test-negative design. This methodology compares vaccination rates among patients who test positive for COVID versus those who test negative, and has been a standard epidemiological tool for evaluating influenza vaccine effectiveness for decades. Researchers and independent epidemiologists, including a Emory University public health expert in an accompanying editorial, defended the design as scientifically sound and well-validated.
Beyond the methodological controversy, the findings align with three other recent studies showing COVID vaccination is associated with reduced risks of major adverse cardiovascular events, emergency care visits, and critical illness — particularly in older adults. The CDC estimates 390,000 to 550,000 COVID-associated hospitalizations occurred during the 2024-2025 season alone.
For health-conscious adults, especially those over 65, these findings support staying current with updated COVID vaccinations as a meaningful, evidence-based strategy to reduce risk of severe illness and hospitalization. The study's publication despite institutional resistance also underscores the importance of independent peer-reviewed journals in preserving scientific integrity.
Key Findings
- 2025-2026 COVID vaccine reduced adult hospitalization risk by 55% and ER visits by 50% in real-world data
- Adults 65+ showed 53% protection against hospitalization and 48% against ER visits from updated vaccine
- Protection was meaningful even accounting for prior vaccination or previous SARS-CoV-2 infection
- Test-negative study design used here is a decades-validated CDC method for routine flu vaccine monitoring
- Three additional studies link COVID vaccination to lower cardiovascular events and critical illness risk
Methodology
This is a news report summarizing a peer-reviewed case-control study published in JAMA Network Open by CDC researchers. The test-negative design is a well-established epidemiological methodology. Source credibility is high: MedPage Today is a reputable medical news outlet and the primary study appeared in a major JAMA-family journal.
Study Limitations
The article is a news summary and does not include full methodology details; readers should consult the primary JAMA Network Open publication. The study covers only the first four months of the 2025-2026 season, so full-season effectiveness may differ. Effectiveness estimates carry confidence intervals and real-world protection varies by individual health status and circulating variants.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: